Suppr超能文献

年龄与肿瘤生物学在细胞减灭术和 HIPEC 后患者术后结局中的交汇。

The Intersection of Age and Tumor Biology with Postoperative Outcomes in Patients After Cytoreductive Surgery and HIPEC.

机构信息

Division of Surgical Oncology, Department of Surgery, Winship Cancer Institute, Emory University, Atlanta, GA, USA.

Division of Surgical Oncology, Department of Surgery, The Ohio State University Wexner Medical Center, Columbus, OH, USA.

出版信息

Ann Surg Oncol. 2020 Dec;27(13):4894-4907. doi: 10.1245/s10434-020-08538-y. Epub 2020 May 6.

Abstract

BACKGROUND

Patient age is a significant factor in preoperative selection for major abdominal surgery. The association of age, tumor biology, and postoperative outcomes in patients undergoing cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) remains ill-defined.

METHODS

Retrospective analysis was performed for patients who underwent a CCR0/1 CRS/HIPEC from the US HIPEC Collaborative Database (2000-2017). Age was categorized into < 65 or ≥ 65 years. Primary outcome was postoperative major complications. Secondary outcomes were non-home discharge (NHD) and readmission. Analysis was stratified by disease histology: non-invasive (appendiceal LAMN/HAMN), and invasive (appendiceal/colorectal adenocarcinoma).

RESULTS

Of 1090 patients identified, 22% were ≥ 65 (n = 240), 59% were female (n = 646), 25% had non-invasive (n = 276) and 51% had invasive (n = 555) histology. Median PCI was 13 (IQR 7-20). Patients ≥ 65 had a higher rate of major complications (37 vs 26%, p = 0.02), NHD (12 vs 5%, p < 0.01), and readmission (28 vs 22%, p = 0.05), compared to those < 65. For non-invasive histology, age ≥ 65 was not associated with major complications or NHD on multivariable analysis. For invasive histology, when accounting for PCI and CCR, age ≥ 65 was associated with major complications (OR 2.04, 95% CI 1.16-3.59, p = 0.01). When accounting for major complications, age ≥ 65 was associated with NHD (OR 2.54, 95% CI 1.08-5.98, p = 0.03). Age ≥ 65 was not predictive of readmission for any histology when accounting for major complications.

CONCLUSIONS

Age ≥ 65 years is an independent predictor for postoperative major complications and non-home discharge for invasive histology, but not non-invasive histology. These data inform preoperative counseling, risk stratification, and early discharge planning.

摘要

背景

患者年龄是进行重大腹部手术术前选择的重要因素。在接受细胞减灭术(CRS)和腹腔热灌注化疗(HIPEC)的患者中,年龄、肿瘤生物学和术后结果之间的关系仍未明确。

方法

对 2000 年至 2017 年期间美国 HIPEC 协作数据库中接受 CCR0/1 CRS/HIPEC 的患者进行回顾性分析。将年龄分为<65 岁或≥65 岁。主要结局为术后主要并发症。次要结局是非居家出院(NHD)和再入院。根据疾病组织学进行分层分析:非侵袭性(阑尾 LAMN/HAMN)和侵袭性(阑尾/结直肠癌腺癌)。

结果

在确定的 1090 名患者中,22%的患者≥65 岁(n=240),59%为女性(n=646),25%为非侵袭性(n=276),51%为侵袭性(n=555)组织学。PCI 中位数为 13(IQR 7-20)。与<65 岁的患者相比,≥65 岁的患者主要并发症发生率更高(37% vs 26%,p=0.02),NHD 发生率更高(12% vs 5%,p<0.01),再入院率更高(28% vs 22%,p=0.05)。对于非侵袭性组织学,多变量分析显示年龄≥65 岁与主要并发症或 NHD 无关。对于侵袭性组织学,在考虑 PCI 和 CCR 后,年龄≥65 岁与主要并发症相关(OR 2.04,95%CI 1.16-3.59,p=0.01)。在考虑主要并发症后,年龄≥65 岁与 NHD 相关(OR 2.54,95%CI 1.08-5.98,p=0.03)。在考虑主要并发症后,对于任何组织学类型,年龄≥65 岁与再入院无关。

结论

对于侵袭性组织学,年龄≥65 岁是术后主要并发症和非居家出院的独立预测因素,但对于非侵袭性组织学不是。这些数据为术前咨询、风险分层和早期出院计划提供了信息。

相似文献

1
The Intersection of Age and Tumor Biology with Postoperative Outcomes in Patients After Cytoreductive Surgery and HIPEC.
Ann Surg Oncol. 2020 Dec;27(13):4894-4907. doi: 10.1245/s10434-020-08538-y. Epub 2020 May 6.
3
Predictors of Non-home Discharge after Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy.
J Surg Res. 2020 Nov;255:475-485. doi: 10.1016/j.jss.2020.05.085. Epub 2020 Jul 1.
4
Non-home Discharge and Prolonged Length of Stay After Cytoreductive Surgery and HIPEC.
J Surg Res. 2019 Jan;233:360-367. doi: 10.1016/j.jss.2018.08.018. Epub 2018 Sep 8.
8
[Efficacy of 1 384 cases of peritoneal carcinomatosis underwent cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy].
Zhonghua Wei Chang Wai Ke Za Zhi. 2021 Mar 25;24(3):230-239. doi: 10.3760/cma.j.cn.441530-20201110-00603.
9
Readmissions After Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy: a US HIPEC Collaborative Study.
J Gastrointest Surg. 2020 Jan;24(1):165-176. doi: 10.1007/s11605-019-04463-y. Epub 2019 Nov 19.
10
Extreme cytoreductive surgery and hyperthermic intraperitoneal chemotherapy: Outcomes from a single tertiary center.
Surg Oncol. 2015 Sep;24(3):264-9. doi: 10.1016/j.suronc.2015.06.013. Epub 2015 Jun 23.

本文引用的文献

1
Cytoreductive surgery and HIPEC for peritoneal carcinomatosis in the elderly.
Int J Surg Oncol. 2014;2014:987475. doi: 10.1155/2014/987475.
2
Outcomes after surgery for esophageal cancer.
Gastrointest Cancer Res. 2007 Sep;1(5):188-96.
3
Clinical results of cytoreduction and HIPEC for malignant peritoneal mesothelioma.
Cancer Treat Res. 2007;134:343-55. doi: 10.1007/978-0-387-48993-3_22.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验